France-based pharmaceutical company Ipsen recently announced that it will be relocating its research and development facility from Milford to East Cambridge. Following the trend of big biotech and pharma companies planning the move to Cambridge, Ipsen signed a long-term lease for 62,600 square feet of lab and office space at 650 Kendall Street in Kendall Square.
Ipsen Pharmaceuticals specializes in creating healthcare solutions for debilitating disease. This new center will focus its research on endocrinology and oncology. With six stories and state-of-the-art facilities, 650 Kendall St provides Ipsen with the perfect setting to continue its high standard of innovation and improve the quality of its products.
It also helps that the Cambridge area offers a multitude of advantages and resources for the biotech/pharma industry. This region is considered to be one of “the preeminent life science communities in the world,” with prestigious universities and med schools, biotech companies, and hospitals all operating in close proximity to Ipsen’s new R&D facility. (Boston Herald)
